S1784Referred to Committee
MAPS Act
Introduced
In Committee
3
Passed One Chamber4
Passed Both5
Signed into Law119th
Congress
2025-05-15
Introduced
7
Cosponsors
S
ⓘType
Sponsor
Gary C. Peters
Democrat · MI · Senator
Votes with party: 82.5% (896 recorded votes)
Full profile: /officials/P000595
Source: Congress.gov · FEC
Cosponsors (7)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Currently in
- Senate Committee on Health, Education, Labor, and PensionsHearings By (full committee) · 2026-03-19
Previously
- Health, Education, Labor, and Pensions CommitteeHearings By (full committee) · 2026-03-19
- Health, Education, Labor, and Pensions CommitteeReferred To · 2025-05-15
- Senate Committee on Health, Education, Labor, and PensionsReferred To · 2025-05-15
Plain-English Summary
Mapping America’s Pharmaceutical Supply Act or the MAPS Act This bill requires the Food and Drug Administration (FDA) to continually update its essential medicines list and identify risks and vulnerabilities in the associated supply chains. In 2020, in response to an executive order, the FDA published a list of essential medicines deemed medically necessary to have available at all times. The bill requires the FDA to update and maintain this list to include drugs and ingredients (1) related to responding to public health threats and emergency incidents, (2) of greatest priority for providing health care and at high risk of shortage, (3) the shortage of which would adversely affect patients with chronic conditions, and (4) that the Department of Defense (DOD) determines to be critical for military preparedness. The FDA must update the list at least every two years. Also, the bill requires the FDA to conduct a risk assessment of the supply chains for drugs and ingredients on the list and annually report its findings to Congress. The assessment must include information about key manufacturing materials, drugs with primarily foreign suppliers, manufacturing capacity, relevant public health and national security risks, and risk mitigation strategies. Additionally, the Department of Health and Human Services, in coordination with other agencies, must map and monitor relevant supply chains to identify vulnerabilities and provide an annual status report to Congress. Finally, DOD must report to Congress every 180 days on the drugs DOD purchased that were manufactured in or sourced from China.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Subjects
Health
Full bill text is not yet cached locally.
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- S528GLRI Act of 2026Passed Senate · 2026-10-05
- S5648TAG ActReferred to Committee · 2026-09-30
- S5555PFAS RAPID Response ActReferred to Committee · 2026-09-24
- S3404Satellite Cybersecurity Act of 2025Passed Senate · 2026-09-24